3 results
Currently, all rotigotine transdermal patches are manufactured at 1 manufacturing site. A second site has been built to manufacture the same patches. Before these patches may be used, it needs to be investigated if they are exactly the same as those…
Primary objectives:Phase 1b:Arm A (BGB-290 + radiation therapy [RT]): Subjects with first-line glioblastoma (GB) with unmethylated MGMT promoter (*unmethylated GB*)• To assess safety and tolerability of BGB-290 combined with RT• To identify dose-…
To evaluate if treatment with only supportive care or addition of one of two anti-COVID-19 agents (chloroquine or hydroxychloroquine) results in less disease progression in patients with moderate to severe COVID-19 who require hospital admission.